Inactief instrument

Andere talen EXPN BIOT Nasdaq Stockholm

Aandelen

SE0008348262

slotkoers Nasdaq Stockholm Andere beurzen
- ^PTS	-

16/05	ExpreS2ion Biotech Holding AB (publ) rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
16/04	ExpreS2ion kondigt de voltooiing aan van het GLP-veiligheidsonderzoek voor ES2B-C001 (HER2-VLP) kandidaat-vaccin tegen borstkanker	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue	13:07
ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens	03/07
ExpreS2ion announces final outcome of its rights issue	01/07
Rights issue subscription period ending 27 June 2024; subscription possible via form	26/06
ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting	24/06
Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine	21/06
ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine	18/06
BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I	14/06
ExpreS2ion CEO to BioStock: "Compelling preclinical package gives us confidence"	12/06
The subscription period in ExpreS2ion's rights issue begins today	12/06
ExpreS2ion to present in upcoming investor and scientific events	10/06
ExpreS2ion publishes prospectus in connection with its rights issue of units	05/06
Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024	05/06
ExpreS2ion Biotech : Interim report for January – March 2024 (Q1)	16/05
ExpreS2ion announces financial results for the first quarter of 2024	16/05
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
ExpreS2ion to present in spring investor events	15/05
ExpreS2ion Biotech : Annual report 2023 including Auditor’s report	08/05
ExpreS2ion annual report for 2023 published	08/05
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	03/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen EXPN BIOT Nasdaq Stockholm

Aandelen

SE0008348262

Andere talen

Filters